Africanews on MSN
South Africa gives twice-yearly HIV prevention jab the green light
It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.
SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...
AllAfrica on MSN
South Africa: SA Becomes The First African Country to Register the Twice-a-year Anti-HIV Jab — at Record Speed
South Africa has become the first African country — and our medicines regulator the third worldwide — to register the ...
The South African Health Products Regulatory Authority (SAHPRA) has registered the drug Lenacapavir, which the World Health ...
South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...
Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...
With millions of South Africans affected by both HIV/AIDS and mental health challenges, leading experts have come together at ...
South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...
Bizcommunity.com on MSN
New hope for HIV prevention in South Africa with lenacapavir approval
The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...
South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...
South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...
AllAfrica on MSN
South Africa: The Six-Monthly Anti-HIV Jab Could be in 360 Clinics by February. Who Should Get the First Doses?
One in ten clinics in South Africa — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab as early as February if the country’s medicines regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results